Chrome Plugin Live! Redefine the way you read FinTwit 🚀 Install Now
Quote Panel
Key Metrics
Fundamentals
Relative Strength
YS
Sector
Top 5 RS in Group
Symbol | Company | RS | 5-Day Perf. |
|---|---|---|---|
Forecast
Analyst rating
Last analyst upgrade/downgrade
Earnings Growth
YoY
Current
Estimates
Q3.23
+1619%
0.22
vs 0.01
Q4.23
N/A
-0.16
vs -0.13
Q1.24
N/A
-0.08
vs NA
Q2.24
N/A
-0.09
vs -0.10
Sales Growth
YoY
Current
Estimates
Q3.23
-50%
96.8M vs 194.1M
Q4.23
-9%
165M vs 181.6M
Q1.24
NA
21.9M vs NA
Q2.24
-86%
24.3M vs 176.3M
Return on Equity
QoQ
Q2.22
+1%
0.01
vs 0.04
Q3.22
+1%
0.01
vs 0.01
Q4.22
NA
NA
vs 0.01
Q1.23
-15%
-0.15
vs NA
Q2.23
-11%
-0.11
vs -0.15
Q3.23
-19%
-0.19
vs -0.11
Q4.23
-17%
-0.17
vs -0.19
Q1.24
-31%
-0.31
vs -0.17
Institutionnal Ownership
prnewswire.com
7 hours ago
prnewswire.com
7 hours ago
seekingalpha.com
9 hours ago
prnewswire.com
16 hours ago
Quote Panel
Key Metrics
Relative Strength
YS
Sector
Top 5 RS in Group
Symbol | Company | RS | 5-Day Perf. |
|---|---|---|---|
YS Biopharma Co., Ltd., a biopharmaceutical company, engages in discovering, developing, manufacturing, and commercializing of vaccines and therapeutic biologics for infectious diseases and cancer. It develops a proprietary PIKA immunomodulating technology platform and a series of preventive and therapeutic biologics targeting Rabies, Coronavirus, Hepatitis B, Influenza, and Shingles. It operates in China, the United States, Singapore, the United Arab Emirates, and the Philippines. The company was founded in 2002 and is based in Beijing, China.
NASDAQ
0.09Â ( 9.68%)
Relative Strenght
27
Volume Buzz
-21%
Earning Acce
No
Dist 52w H.
43%Forecast
259%2024-Revenue
-286%2024-EPS
-91%2024-EBITDA
Analyst rating
Strong Sell
Sell
Buy
Neutral
Strong Buy
Price Target
NaN(-100.00%)
Number of analyst
Last analyst upgrade/downgrade
No Data Available
